



Updated Monthly

March 13, 2024

Prepared for:



THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:




Questions?

Liz Powell, Esq., MPH

lpowell@G2Gconsulting.com

www.G2Gconsulting.com

  @G2Gconsulting





GBG Report

Updated Monthly

March 13, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

TABLE OF CONTENTS

New Opportunities

Advanced Research Projects Agency for Health	2
Agriculture.....	3
Biotechnology and Biomanufacturing.....	3
Cancer	3
Cardiovascular and Pulmonary Health.....	5
Central Nervous System	5
Climate Science	6
Cognitive and Brain Health.....	6
Communication Disorders.....	8
Complementary and Integrative Health.....	8
Coronavirus	8
Dental and Craniofacial Research	9
Diagnostics	9
Energy Science	10
Genomics	11
Health Equality	11
Health IT & Data.....	12
HIV/AIDS	12
Immunology & Infectious Disease	13
Measurement Science	14
Medical Countermeasures.....	14

Military Burn.....	15
Musculoskeletal Health	15
Palliative Care.....	16
Patient-Centered Research	16
Rare Diseases	17
Substance Use Disorder	18
Therapeutics.....	18
Veterinary Medicine.....	19
Women's Health.....	20

Recurring Opportunities

Advanced Research Projects Agency for Health	21
Air Force	21
Army.....	22
BARDA	24
DARPA	24
Defense Threat Reduction Agency	24
Department of Energy.....	25
Navy	25

GBG Acronyms	26
---------------------------	----



March 21, 2024 – Join us for G2G’s Monthly [Non-Dilutive Funding: GBG Reporting Service Webinar](#) at 12-12:30pm EDT (FREE to all) and 12:30-1:00pm EDT (premium service private consultation for G2G and GBG clients). If you’re an affiliate of BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Health Industry Forum, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, or VaBio – your membership gets you access to the private consultation webinar.

Women’s Health News: G2G CEO Liz Powell has co-founded the **Women’s Digital Health Network**. [Learn more](#) and join! G2G is also sponsoring a [forum on funding for Women’s Health](#) on **March 21 at 1pm EDT**. If you are an innovator, founder, funder, researcher, or care about driving meaningful change in advancing the health of women, this event is for you!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (2)		
1.	Transplantation of Human Eye Allografts (THEA) (ARPA-H) 75N99224R0002	The THEA program aims to make whole eye transplantation a reality for the recovery of vision loss in patients with total blindness from retinal and optic nerve disease. We believe the great advancements over the last two decades in technology, transplantation surgery, and regenerative medicine now make restoration of vision from whole eye transplantation possible. https://sam.gov/opp/f90a380d7f4549a8a5ec97be9d967576/view	Dependent upon proposal and available funding	Proposal: 4/25/24
2.	ARPA-H Sprint for Women’s Health (ARPA-H) ARPA-H-SOL-24-107	The RFS invites Solution Summary submissions on the following six topics of interest in women’s health for either the Spark or Launchpad track. Spark awards will focus on transformative early-stage research efforts; Launchpad awards aim to accelerate later-stage transformative health solutions reaching the public. Topic 01: Women’s Health at Home; Topic 02: Prioritizing Ovarian Health Through Mid-Life To Prevent Disease; Topic 03: ARTEMIS—Advancing Research Through Enhanced Models for Investigating the Influence of Sex Differences on Health Outcomes; Topic 04: Advancing Women’s Brain Health Via Lymphatic Targeting; Topic 05: Objective and Quantitative Measurement of Chronic Pain in Women; Topic 06: Wild Card: Revolutionary Breakthroughs in Women’s Health. https://sprint.investorcatalysthub.org/request-for-solutions/	Up to \$10 million Dependent upon award mechanism	Solution Summaries: 4/12/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGRICULTURE (1)		
3.	Special Research Grants Program Aquaculture Research (USDA/NIFA) USDA-NIFA-SRGP-010575	The Aquaculture Research program will fund projects that directly address major constraints to the U.S. aquaculture industry and focus on one or more of the following program priorities: (1) genetics of commercial aquaculture species; (2) critical disease issues impacting aquaculture species; (3) design of environmentally and economically sustainable aquaculture production systems; and (4) economic research for increasing aquaculture profitability. https://www.nifa.usda.gov/grants/funding-opportunities/special-research-grants-program-aquaculture-research	Up to \$300,000	Proposal: 4/15/24
		BIOTECHNOLOGY AND BIOMANUFACTURING (2)		
4.	Ideas Lab: Use-Inspired Acceleration of Protein Design (NSF) NSF 24-550	The USPRD initiative will accelerate the translation of novel approaches to protein design and enable new applications of importance to the U.S. bioeconomy. USPRD aims to advance protein design and its applications to the next level by: Accelerating the use of protein design technologies to enable applications beyond human therapeutics; Extending the range of accurate prediction models to enable the design of enzymes and families of enzymes. https://new.nsf.gov/funding/opportunities/ideas-lab-use-inspired-acceleration-protein-design/nsf24-550/solicitation	Up to \$3.75 million per year, for up to 3 years	Preliminary proposal: 4/23/24 Full proposal: 8/30/24
5.	Ideas Lab: Advancing Cell-Free Systems Toward Increased Range of Use-Inspired Applications (NSF) NSF 24-552	CFIRE aims to: 1. Reduce the cost of cell-free systems; 2. Increase the range and capabilities of cell-free systems; and 3. Develop and demonstrate cost-effective use-inspired applications. The objective is to place cell-free technology on an exponential growth path in which reduced costs lead to increasing adoption which, in turn, generates the learning and investment required to further reduce costs. https://new.nsf.gov/funding/opportunities/ideas-lab-advancing-cell-free-systems-toward/nsf24-552/solicitation	Up to \$3.75 million per year, for up to 3 years	Preliminary proposal: 5/17/24 Full proposal: 9/20/24
		CANCER (30)		
6.	ADvanced Analysis for Precision cancer Therapy (ADAPT) Program (ARPA-H) ARPA-H-MAI-24-01-03	The ADvanced Analysis for Precision cancer Therapy (ADAPT) Program will develop an adaptive cancer treatment platform that detects when tumors change, recommends updates to the treatment plan, and evaluates revised plans through a novel clinical trial design. The ADAPT program will examine a tumor's behavior as it changes and will then match each patient's evolving cancer with the best available therapy. ADAPT will revolutionize cancer care by bringing new science and medicine together to map and target tumor changes that improve survival for patients with metastatic cancer. https://sam.gov/opp/0ee8d3e84cfc4319bd9a54468728fc3/view	Up to \$25 million, for up to 6 years Dependent upon award mechanism	Proposal: 5/6/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
7.	NOSI: Telehealth Research in Cancer Care (NIH/NCI) NOT-CA-24-033	The scope of telehealth research encompassed by this NOSI includes (a) synchronous and asynchronous communications and other digital interactions between clinicians and patients, (b) communications and other digital interactions between and among clinicians, and (c) the evaluation of telehealth policy changes on cancer care access, outcomes, and health equity. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-033.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 3/16/26
8.	NOSI: Epidemiologic Studies to Assess the Impact of Incretin Mimetics on New and Recurrent Cancer Risk (NIH/NCI) NOT-CA-24-037	This NOFO aims to solicit submission of innovative epidemiologic research designed and focused on facilitating and enhancing our understanding of the impact of long-term incretin mimetic use on cancer risk and outcomes among individuals with and without comorbid conditions. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-037.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/26
9.	Forecast: FY24 Melanoma Research Program (DoD/CDMRP)	Five awards are anticipated: Survivorship and Patient Wellness Research; Focused Program Award – Rare Melanomas; Idea Award; Melanoma Academy Scholar Award; Team Science Award. Certain applications must address at least one Focus Area . https://cdmrp.health.mil/pubs/press/2024/24mrppreann	Up to \$2 million, for up to 4 years Dependent upon award mechanism	TBD
10.	Forecast: FY24 Pancreatic Cancer Research Program (DoD/CDMRP)	Three awards are anticipated in the PCARP: Idea Development Award; Translational Research Partnership Award; and Focused Pilot Award. All FY24 PCARP applications must address one or more Focus Areas . https://cdmrp.health.mil/pubs/press/2024/24pcarppreann	Up to \$650,000, for up to 3 years Dependent upon award mechanism	TBD
11.	Forecast: FY24 Prostate Cancer Research Program (DoD/CDMRP)	Six awards are anticipated: Data Science Award; Early Investigator Research Award; Exploration – Hypothesis Development Award; Idea Development Award; Implementation Science Award; Physician Research Award. Applications are required to address one or more of the FY24 PCRP Overarching Challenges . https://cdmrp.health.mil/pubs/press/2024/24pcrppreann	Up to \$2 million, for up to 4 years Dependent upon award mechanism	TBD
12.	Point-of-Care Tools to Improve Detection of Pre-Cancer and Early Cancer in Medically Under-Served Settings (POCTRN)	This solicitation prioritizes support for point-of-care (POC) tests to improve screening, early detection and/or diagnosis of pre-cancers and early cancers that arise in epithelial surfaces in organ sites accessible for early detection, because this is where point-of-care technologies can have the most immediate impact. https://www.poctrn.org/citec-solicitation-2024	Up to \$100,000, for up to 1 year	Expression of interest: 3/31/24 Invited proposal: 6/2/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH (2)		
13.	Forecast: Strategies for Preventing Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes (Collaborative UG3/UH3 Clinical Trial Required) (NIH/NHLBI) NOT-HL-24-003	This RFA will support a multisite clinical trial that will test a screening approach to identify coronary atherosclerosis and test interventions to reduce the progression of coronary atherosclerosis. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-24-003.html	TBD	Estimated post date: 6/13/24 Estimated proposal date: 10/14/24
14.	Center for Advancing Point of Care Technologies in Heart, Lung, Blood and Sleep Disorders (POCTRN)	CAPCaT announces the 2024 solicitation of grant applications focused on developing, adapting, or validating point of care technologies that can be rapidly deployed to enhance the diagnosis, monitoring, management, and prevention of heart, lung, blood, or sleep disorders, with additional interest in projects that incorporate complementary and integrative health approaches. https://www.poctrn.org/capcat-solicitation-2024	Up to \$100,000, for up to 1 year	Expression of interest: 3/31/24 Invited proposal: 6/2/24
		CENTRAL NERVOUS SYSTEM (9)		
15.	Translational Neural Devices (R61/R33 - Clinical Trial Optional) (NIH/NINDS) PAR-24-151	This NOFO encourages investigators to pursue translational activities and small clinical studies to advance the development of low risk therapeutic and diagnostic devices for disorders that affect the nervous or neuromuscular systems. http://grants.nih.gov/grants/guide/pa-files/PAR-24-151.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 1/28/27
16.	Forecast: FY24 Multiple Sclerosis Research Program (DoD/CDMRP)	Four awards are anticipated: Clinical Trial Award; Early Investigator Research Award; Exploration - Hypothesis Development Award; Investigator-Initiated Research Award. Applications must address one or more of the Focus Areas specific to each funding mechanism. https://cdmrp.health.mil/pubs/press/2024/24msrppreann	Up to \$4 million, for up to 4 years Dependent upon award mechanism	TBD
17.	Forecast: FY24 Spinal Cord Injury Research Program (DoD/CDMRP)	Four awards are anticipated: Clinical Trial Award; Clinical Translation Research Award; Translational Research Award; Investigator-Initiated Research Award. Applications must address one or more of the Focus Areas . https://cdmrp.health.mil/pubs/press/2024/24scirppreann	Up to \$3.1 million, for up to 4 years Dependent upon award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CLIMATE SCIENCE (4)		
18.	NOSI: Innovative Technologies for Research on Climate Change and Human Health (NIH) NOT-ES-24-002	This NOSI encourages grant applications to develop commercializable tools, resources, and approaches to capture the effects of climate change and the associated impacts of extreme weather events on human health, and to support adaptation or mitigation strategies to minimize health hazards and impacts from climate change. https://grants.nih.gov/grants/guide/notice-files/NOT-ES-24-002.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 4/5/25
		COGNITIVE AND BRAIN HEALTH (13)		
19.	Forecast: NINDS Program Project Grant (P01 Clinical Trial Optional) (NIH/NINDS) NOT-NS-24-070	This NOFO will solicit applications for innovative, interactive research to answer significant scientific questions that are important for the mission of NINDS, via a synergistic collaboration between outstanding scientists who might not otherwise collaborate. The program project grant is designed to support research in which the funding of several interdependent highly meritorious projects as a group offers significant scientific advantages over support of these same projects as individual research grants. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-070.html	TBD	Estimated post date: 4/1/24 Estimated proposal date: 5/25/24
20.	Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed) (NIH/NINDS/NIA) PAR-24-147	This NOFO supports investigations with a minimum of two Alzheimer's Disease-Related Dementias (ADRD) co-pathologies, with or without risk factors and comorbidities, in the same model system to identify cellular and molecular mechanisms of how and when these multi-pathology interactions drive worsening ADRD pathophysiology and phenotypic outcomes, such as cognitive, behavioral, or functional impairment. https://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html	Up to \$500,000 per year, for up to 5 years	Proposal: 6/4/24
21.	Investigating Distinct and Overlapping Mechanisms in TDP-43 Proteinopathies, including in LATE, FTD & other ADRDs (R01 - Clinical Trial Not Allowed) (NIH/NINDS/NIA) PAR-24-148	This NOFO supports studies establishing deeper mechanistic insights and causal cellular and molecular relationships between TDP-43 pathology and phenotypic outcomes. Additionally, it requires comparisons between at least two TDP-43 proteinopathies, one of which must be an ADRD. https://grants.nih.gov/grants/guide/pa-files/PAR-24-148.html	Up to \$500,000 per year, for up to 5 years	Proposal: 6/4/24
22.	Open Measurement Coordinating Network for Non-Pharmacological AD/ADRD Primary Prevention Trials (U24 CT Not Allowed) (NIH/NIA) RFA-AG-25-005	The Network will serve as a centralized hub for developing, validating, standardizing, and disseminating measures and measurement methods for AD/ADRD primary prevention trials. It will incorporate measures and measurement methods across neuropsychological, biomarker, and functional domains to meet the goal of primary prevention of AD/ADRD centered around brain health equity. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-005.html	Dependent upon proposal, for up to 5 years	Letter of intent: 5/15/24 Proposal: 6/15/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
23.	Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed) (NIH/NIA) RFA-AG-25-016	This NOFO invites applications proposing to establish multi-scale computational models recapitulating dynamic changes associated with aging and AD/ADRD. This broad scope encompasses a variety of computational approaches to better understand aging processes and AD/ADRD across molecules, cells and networks, and cognition and behavior. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-016.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 5/13/24 Proposal: 6/13/24
24.	BRAIN Initiative: Scaled reagent resources; and production and distribution facilities for brain cell type-specific access across vertebrate species (U01/U24 Clinical Trial Not Allowed) (NIH) RFA-MH-25-100 (U01) RFA-MH-25-105 (U24)	These NOFOs are intended to support the scaling up of brain cell type-specific molecular or genetic access reagents to study circuit function; and dissemination facilities for scaled-up production and distribution of a specific set of brain cell type-specific access reagents to study circuit function. Projects will integrate: scaled engineering, validation, cataloguing, and adaptation into easily disseminable formats of reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to hundreds of brain cell types. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-100.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-105.html (U24)	Dependent upon proposal, for up to 5 years	Letter of intent: 5/14/24 Proposal: 6/14/24 (U01) Letter of intent: 10/1/25 Proposal: 10/31/25 (U01)
25.	Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed) (NIH/NINDS/NIA) RFA-NS-24-032	This NOFO supports the development and validation of novel, complex, and pathophysiologically relevant human cellular models of ADRD. Human cellular models could be developed and validated with the goal of supporting therapeutic development or better understanding of human disease mechanisms and mechanisms that cause predisposition or resilience to developing ADRD. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-032.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 5/20/24 Proposal: 6/20/24
26.	Forecast: FY24 Traumatic Brain Injury and Psychological Health Research Program (DoD/CDMRP)	Five awards are anticipated: Clinical Trial Award; Focused Program Award; Health Services Research Award; Translational Research Award; Emerging Research Award. Applications must address one or more of the Focus Areas , and the Emerging Research Award has additional Topic Areas . https://cdmrp.health.mil/pubs/press/2024/24tbiphrrpreann	Up to \$5 million, for up to 4 years Dependent upon award mechanism	TBD



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMMUNICATION DISORDERS (1)		
27.	NIDCD Early Career Research(ECR) Award (R21 Clinical Trial Optional) (NIH/NIDCD) PAR-24-119	The research must be focused on one or more of the areas within the biomedical and behavioral scientific mission of the NIDCD: hearing, balance, smell, taste, voice, speech, or language. The NOFO supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new research technology. https://grants.nih.gov/grants/guide/pa-files/PA-24-119.html	Up to \$125,000 per year, for up to 3 years	Multiple deadlines; NOFO open through 2/17/27
		COMPLEMENTARY AND INTEGRATIVE HEALTH (1)		
28.	Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01 Clinical Trial Not Allowed) (NIH/NCCIH/ODS) RFA-AT-24-008	This NOFO will support development, adaptation, and/or applications of computational tools to aggregate and analyze orthogonal chemical and/or biological data sets related to natural products with the aim of generating novel testable hypotheses regarding their biological activity and role in the context of whole person health research. https://grants.nih.gov/grants/guide/rfa-files/RFA-AT-24-008.html	Up to \$500,000 per year, for up to 5 years	Letter of intent: 5/28/24 Proposal: 6/28/24
		CORONAVIRUS (4)		
29.	Project NextGen: COVID-19 Monoclonal Antibody Therapeutics for Treatment (BARDA/RRPV) RPP-24-03-Treatment	The purpose of this project is to partner with developers and other organizations to advance the clinical development of Next-Generation Therapeutics for COVID-19, specifically treatment. The goal of this project is to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. https://www.rpv.org/solicitation/rpp-24-03-treatment/	Dependent upon proposal and award mechanism	Proposal: 4/8/24
30.	NextGen Vaccines: Immune Assays (BARDA/RRPV) RPP-24-04-NGVxAssays	The purpose of this project is to partner with performers to establish multiparameter intracellular staining (ICS) assays as part of a centralized testing resource for Project NextGen vaccine trials. The goal of this project is to establish multiparameter ICS assays to identify and quantify SARS-CoV-2-specific T-cell subsets in peripheral blood mononuclear cell (PBMC) samples. https://www.rpv.org/uncategorized/rpp-24-04-ngvxassays/	Dependent upon proposal and award mechanism	Proposal: 3/18/24
31.	NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis (BARDA/RRPV) RPP-24-04-NGVxStats	BARDA intends to leverage immunogenicity data from multiple clinical trials of investigational next-generation COVID-19 vaccines and FDA licensed or authorized COVID-19 vaccines to inform a broader understanding of immunologic correlates of vaccine protection. https://www.rpv.org/solicitation/rpp-24-04-ngvxstats/	Dependent upon proposal and award mechanism	Proposal: 3/25/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CORONAVIRUS		
32.	Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines (HHS/BARDA) RRPV-24-05-NGClinMfg	The purpose of this initiative is to partner with developers and other organizations to implement novel solutions to cGMP manufacturing hurdles and enable clinical trials for next-generation COVID-19 vaccines. The goal of these Project Awards is to advance innovative capabilities and improve the vaccine manufacturing enterprise to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. https://www.rpv.org/solicitation/24-05-ngclinmfg/	Total funds of \$160 million	Proposal: 4/19/24
		DENTAL AND CRANIOFACIAL RESEARCH (4)		
33.	Military Dental Research – Seeking New Technologies and Development Partners (MTEC) MTEC-24-07-NavyDental	This RPP focuses on detection, prevention, and treatment of dental diseases, oral infections, maxillofacial injuries, and orofacial pain to improve care for and outcomes of wounded warfighters. Research topics may encompass routine clinical dental care to maintain the resilience and readiness of the warfighter as well as methods or products to treat injuries to the oral cavity, face, and facial bones sustained during combat. https://mtec-sc.org/wp-content/uploads/2024/03/MTEC-24-07-NavyDental-RPP.pdf	Up to \$3 million, for up to 26 months	Enhanced white paper: 4/26/24
34.	NOSI: Determining the Tri-directional Relationship Among Oral Health, Nutrition, and Comprehensive Health (NIH/NIDCR) NOT-DE-24-011	The purpose of this NOSI is to support research to better understand the mechanisms of the tri-directional relationship among nutrition, systemic health, and oral, dental, and craniofacial (DOC) health and the development of nutritional interventions in the dental setting. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-24-011.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/7/27
		DIAGNOSTICS (6)		
35.	Addressing Health Inequities in Clinical Diagnostics (R41/R42/R43/R44 Clinical Trials Not Allowed) (NIH) PAR-24-157 (R41/R42) PAR-24-158 (R43/R44)	These NOFOs encourage applications to pursue the development of improved clinical diagnostics or the development of alternative clinical diagnostics that address health disparities created by clinical laboratory assays and/or point-of-care devices that fail to incorporate diverse patient groups. https://grants.nih.gov/grants/guide/pa-files/PAR-24-157.html (R41/R42) https://grants.nih.gov/grants/guide/pa-files/PAR-24-158.html (R43/R44)	Up to \$306,872, for up to one year (Phase I) Up to \$2,045,816, for up to 2 years (Phase II) Waiver topics may exceed these amounts	Multiple deadlines; NOFOs open through 1/5/27



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DIAGNOSTICS		
36.	ACME POCT Call for Proposals: Microsystems-based Point-of-Care Technologies (POCTRN)	ACME POCT seeks to support the development, adaptation, or validation of microsystems-based point-of-care (POC) medical technologies. These technologies may be comprised of optical, electronic, microelectromechanical (MEMS) or other types of sensors, biosensors, microfluidic components, or even smartphone-based systems. https://www.poctrn.org/acme-solicitation-2024	Up to \$250,000 of in-kind support, for up to 1 year	Expression of interest: 3/31/24 Invited proposal: 6/2/24
37.	Forecast: Biothreat Diagnostic Rapid Response (DxR2) (BARDA/RRPV)	Biothreat diagnostic test development and ready-production capacity to rapidly produce tests https://www.rrpv.org/opportunities/	TBD	Estimated post date: Q2 FY24
38.	Improvements To Rapid Simple Point-Of-Care Tests For Sexually Transmitted Infections (POCTRN)	The Johns Hopkins University Center for Innovative Diagnostics for Infectious Diseases is seeking to facilitate the development of novel detection technologies for point-of-care tests (POCT). The targets for these POCT are limited to sexually transmitted infections (STIs) including infections diagnosed in blood such as Hepatitis C virus (HCV), syphilis, and Human Immunodeficiency virus (HIV). https://www.poctrn.org/jhu-solicitation-2024	Up to \$200,000, for up to 1 year	Expression of interest: 3/31/24 Invited proposal: 6/2/24
39.	PORTENT: Point-of-Care Technologies for Nutrition, Infection, and Cancer for Global Health Announcement of Funding Opportunity (POCTRN)	PORTENT is focused on supporting development, clinical validation, commercialization, and deployment of point-of-care technologies for nutrition, infection, and cancer for global health in locations where access to better diagnostics can have the largest worldwide impact. https://www.poctrn.org/portent-solicitation-2024	Up to \$100,000, for up to 1 year	Expression of interest: 3/31/24 Invited proposal: 6/2/24
		ENERGY SCIENCE (4)		
40.	Inflation Reduction Act Funding for Advanced Biofuels (DoE) DE-FOA-0003178	This FOA supports the goal of producing 3 billion gallons of sustainable aviation fuel (SAF) per year and reduce aviation emissions by 20% by 2030. This FOA also supports high-impact technology R&D to accelerate the bioeconomy. Two topic areas are: Pre-pilot Scale-Up of Integrated Biorefinery Technologies; Biointermediate Processing Toolbox. https://eere-exchange.energy.gov/Default.aspx#Foalda7e46a25-6d10-49c5-aa54-8c054bc399a8	Total funds of \$9.4 million	Concept paper: 3/22/24 Proposal: 5/24/24
41.	Regional Resource Hubs for Purpose-Grown Energy Crops (DoE) DE-FOA-0003209	The FOA addresses enabling the mobilization of low carbon intensity purpose-grown energy crops across varied agronomic and geographic landscapes through the generation of data and research findings. https://www.grants.gov/search-results-detail/352261	Up to \$10 million	Proposal: 6/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENERGY SCIENCE		
42.	Forecast: Mixed Algae Conversion Research Opportunity (MACRO) (DoE) DE-FOA-0003276	This FOA will seek to address R&D challenges in converting various seaweeds, other waste algae and wet waste feedstocks to low-carbon fuels, chemicals, and agricultural products. These feedstocks are readily available today but are underutilized and are difficult to convert due to their variability, unique chemical compositions, and storage instability. https://www.grants.gov/search-results-detail/352329	Up to \$19 million in total funds	Estimated post date: March 2024
43.	BioLogical Undersea Energy (BLUE) (DoD/DARPA) HR001124S0010	The BLUE program seeks to develop power supplies that capture and convert microscopic forms of marine biomass and other substances into electrical power. These power supplies are intended for onboard use by ocean-deployed sensor systems presently powered by batteries. BLUE power supplies will enable high capability and long endurance ocean-deployed sensor systems. https://sam.gov/opp/78e3b1374f5b415c82cc2c85d54a8481/view	Dependent upon proposal and award mechanism	Abstract: 3/14/24 Proposal: 4/30/24
		GENOMICS (4)		
44.	NOSI: Advancing Genomic Medicine Research through Small Businesses (NIH/NHGRI) NOT-HG-24-016	NHGRI seeks applications to research and develop innovative solutions with commercial potential, such as new clinical services, computer software, mobile apps, and other products, that enable the use of genomic information in clinical care for individuals of all racial/ethnic backgrounds and socioeconomic statuses. https://grants.nih.gov/grants/guide/notice-files/NOT-HG-24-016.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/6/26
		HEALTH EQUALITY (6)		
45.	NOSI: U.S. Health in the International Perspective (NIH/NIA) NOT-AG-24-004	This NOSI expresses NIA's interest in research that examines mechanisms and causes behind the increasing U.S. health disadvantage, which refers to worsening life expectancies and health outcomes in the U.S. compared to other countries. Of particular interest are projects that examine cross-national and U.S. cross-regional or cross-state differences in policy context that may drive poor health outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-004.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/27
46.	Innovations and Technologies for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44/R41/R42- Clinical Trial Optional) (NIH) RFA-MD-24-006 (R43/R44) RFA-MD-24-007 (R41/R42)	These NOFOs invite grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more populations that experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable. https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-24-006.html (R43/R44) https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-24-007.html (R41/R42)	Up to \$306,872, for up to one year (Phase I) Up to \$2,045,816, for up to 2 years (Phase II) Waiver topics may exceed these amounts	Multiple deadlines; NOFOs open through 12/9/26



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT & DATA (1)		
47.	NOSI: Validation of Digital Health and AI/ML Tools for Improved Assessment in Biomedical and Behavioral Research (NIH) NOT-CA-24-031	Research supported by this NOSI is expected to provide support for analytical and/or clinical validation of recently developed digital health and AI/ML technologies. Digital health and AI/ML technologies are defined broadly to include any health technology leveraging mobile health, health information technology, wearable devices, sensors, telehealth and telemedicine, internet of things (IoT), SaMD and/or related AI/ML algorithms and tools to monitor and manage health across the life course. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-24-031.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/5/25
		HIV/AIDS (13)		
48.	Forecast: Cell and Gene Therapies for HIV Cure: Developing a Pipeline (Po1 Clinical Trial Not Allowed) (NIH/NIAID) NOT-AI-24-015	The goal of this NOFO is to support integrated multi-project research Programs to apply emerging and improved technologies, alone or in combination, to the development of innovative gene- and/or cell-based HIV cure approaches, defined as either sustained viral remission in the absence of antiretroviral treatment or elimination of HIV infection from the body. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-015.html	Up to \$2.2 million	Estimated post date: 4/1/24 Estimated proposal date: 7/30/24
49.	NOSI: Interventions to Reduce Chronic Inflammation and Inflammation-Related Morbidity in People Living with HIV/AIDS (NIH/NCCIH/NIA) NOT-AT-24-035	The main objective of this NOSI is to encourage applications for clinical and basic and mechanistic research to develop, refine, and/or test interventions that reduce or prevent chronic HIV-associated inflammation, and evaluate whether this ultimately reduces the sequelae of that inflammation. https://grants.nih.gov/grants/guide/notice-files/NOT-AT-24-035.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 11/13/24
50.	Forecast: Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed) (NIH/NIMH/NINDS) NOT-NS-24-065	This NOFO will solicit applications that propose the development and early stage validation of novel humanized small animal models and/or human cellular microphysiological systems for NeuroHIV preclinical research. The goal of this initiative is to promote a significant improvement in the translational relevance of NeuroHIV models, specifically in the context of chronic HIV infection of the CNS in the modern antiretroviral therapy (ART) era under conditions of viral suppression. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-065.html	Up to \$750,000	Estimated post date: 6/5/24 Estimated proposal date: 10/21/24
51.	Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional) (NIH/NIDDK) PAS-24-163	Topics within the scope of NIDDK's mission often cut across priority HIV/AIDS research areas. These include fundamental studies of the gastrointestinal and penile microbiomes or gastrointestinal and penile mucosal immunology that may be important to our understanding of CCCs, viral reservoirs, or other priority NIH HIV/AIDS research. https://grants.nih.gov/grants/guide/pa-files/PAS-24-163.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFOs open through 1/7/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
52.	Impact of Comorbidities and Co-Infections on HIV Reservoirs (R01 Clinical Trial Not Allowed) (NIH) RFA-DK-25-013	This NOFO seeks to foster new multi-disciplinary teams to address how HIV Comorbidities and co-infections within the missions of NIDDK and NIAID interact with viral reservoirs, potentially confounding cure strategies aimed at either sustained viral suppression or elimination from the body. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-013.html	Dependent upon proposal, for up to 5 years	Letter of intent: 5/30/24 Proposal: 7/30/24
53.	Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed) (NIH) RFA-MD-24-005	This initiative supports research to determine the underlying mechanisms that contribute to health disparities in HIV and aging and how multiple comorbidities influence overall health outcomes and quality of life among people with HIV from populations that experience health disparities. https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-24-005.html	Up to \$500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 1/7/26
54.	Point-of-Care Technologies for HIV/AIDS, Co-morbidities, and Emerging Infectious Disease in Low- and Middle-Income Countries (POCTRN)	C-THAN seeks collaborative research projects to develop novel point-of-care technologies (POCT) aimed at improving diagnosis and treatment monitoring of HIV/AIDS or the detection of emerging or reemerging infectious disease in low- and middle-income countries (LMIC). https://www.poctrn.org/c-than-solicitation-2024	Up to \$100,000, for up to 1 year	Expression of interest: 3/31/24 Invited proposal: 6/2/24
		IMMUNOLOGY & INFECTIOUS DISEASE (6)		
55.	NCHHSTP Epidemiologic and Economic Modeling for HIV, Viral Hepatitis, STD, and TB (CDC/NCHHSTP) CDC-RFA-PS-24-0028	This NOFO will support modeling of disease dynamics and advanced data analytics to inform and improve HIV, viral hepatitis, STD, and TB epidemics, interventions, and programs. This NOFO will incorporate new modeling approaches, continue to enhance existing models that guide informed decision-making, provide tools and data for prioritizing public interventions and programs, and to guide the allocation of scarce program resources. https://www.grants.gov/search-results-detail/349740	\$1 million average per year, for up to 5 years	Proposal: 4/8/24
56.	Center of Excellence for Systems Modeling of Infection and Immunity across Biological Scales (U54 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-23-077	This NOFO supports the establishment of one (1) Center of Excellence (CoE) to coordinate the research community of infectious and immune-mediated disease (IID) computational modelers and advance IID modeling research across biological scales. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-23-077.html	Up to \$3.125 million per year, for up to 5 years	Letter of intent: 5/4/24 Proposal: 6/4/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
57.	Forecast: Central Influenza and Emerging Infectious Diseases Vaccine Immunogenicity Laboratory (BARDA/RRPV)	Laboratories to provide centralized immunogenicity assay capabilities to support advanced research and development of pandemic influenza virus vaccines and emerging infectious diseases vaccines, including support for Phase 1, 2, 3 clinical trial endpoints. https://www.rpv.org/opportunities/	TBD	Estimated post date: Q2 FY24
58.	Forecast: FY24 Tick-Borne Disease Research Program (TBD RP) (DoD/CDMRP)	Two awards are anticipated: Idea Development Award (IDA) and Therapeutic/Diagnostic Research Award (TDRA). Applications must be relevant to at least one of the appropriate focus areas . Applicants are encouraged to submit applications focused on persistent Lyme disease, and other tick-borne diseases and conditions endemic to the U.S. https://cdmrp.health.mil/pubs/press/2024/24tbdrrpreann	Up to \$830,000, for up to 3 years Dependent upon award mechanism	TBD
59.	Forecast: mRNA Vaccine Platform Production Capability for Rapid Pandemic and Priority Threat Response (BARDA/RRPV)	The primary focus of this project is the development of an mRNA vaccine platform production capability applied first to influenza viruses that can be exercised over time to respond rapidly and flexibly to pandemic influenza and develop vaccines to other priority threats. https://www.rpv.org/opportunities/	TBD	Estimated post date: Q2 FY24
		MEASUREMENT SCIENCE (2)		
60.	Measurement Science and Engineering (MSE) Research Grant Programs (DoC/NIST) 2024-NIST-MSE-01	Grant programs support activities in fields such as: bioscience, chemistry, dimensional metrology, electronics, engineering, infrastructure, information technology, manufacturing, manufacturing metrology, materials science and engineering, nanotechnology, neutron research, optics, and physics. https://www.grants.gov/search-results-detail/352807	Dependent upon proposal and award mechanism	Proposals accepted through 3/5/26
61.	Precision Measurement Grant Program (PMGP) (DoC/NIST) 2024-NIST-PMGP-01	The PMGP is seeking applications from eligible applicants to support significant research in the field of fundamental measurement or the determination of fundamental constants. https://www.grants.gov/search-results-detail/352281	Up to \$50,000 per year, for up to 3 years	Pre-Application: 4/9/24 Invited proposal: 5/9/24
		MEDICAL COUNTERMEASURES (2)		
62.	Preclinical Testing Services for Botulinum Neurotoxin Therapeutics (BARDA)	The BoNT-CTTS supports preclinical testing of therapeutic candidates (e.g., small molecules, antibodies, and other biologics) in efficacy models of botulinum intoxication. BoNT-CTTS accepts candidate therapeutics for evaluation from academic researchers; industry, including small businesses; and other institutions. https://www.medicalcountermeasures.gov/barda/cbrn/antivirals-antitoxins/	N/A	BARDA will evaluate therapeutic candidates on a rolling basis.



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES		
63.	Medical Threat Reduction Challenge (MCDC/ATI)	Support national defense efforts with your technology in the following areas: PREVENTION: Vaccine manufacturing platforms, needle free delivery platforms, mRNA vaccines for biological threat agent diseases, vaccine encapsulation technologies, vaccine capability areas, accelerated antibodies prototype development, etc.; TREATMENT: Reactivating and consolidated nerve agent treatment systems, small molecule therapeutics, therapeutics capability areas, gene-encoded MCM development and response platforms, etc.; DIAGNOSTICS: CBRN medical decision systems and agent identification, opioid exposure diagnosis, microphysiological systems, advanced diagnostic capabilities, etc. https://www.techconnectworld.com/World2024/MCDC-Challenge/	Up to \$50,000; finalists will pitch at TechConnectWorld	Proposal: 3/28/24
		MILITARY BURN (2)		
64.	Forecast: FY24 Military Burn Research Program (DoD/CDMRP)	Two awards are anticipated: Patient-Centered Research Award and Technology/Therapeutic Development Award. Applications must be relevant to at least one of the appropriate focus areas: Atypical Burns, Burn Knowledge Products, Burn injury-related complications. https://cdmrp.health.mil/pubs/press/2024/24mbrppreann	Up to \$2.2 million, for up to 4 years Dependent upon award mechanism	TBD
		MUSCULOSKELETAL HEALTH (9)		
65.	NOSI: Mechanisms of Osteoarthritis (NIH/NIA/NIAMS) NOT-AG-24-002	This NOSI invites applications on research employing genetically defined and/or modified mouse models, other animal models such as dogs and monkeys, or archived human joint tissues to explore the biological mechanisms underlying the initiation and progression of osteoarthritis (OA). It is intended to encourage novel approaches to accelerate development and characterization of emerging or under-explored models as well as testing hypotheses that will lead to an improved understanding of the origins and mechanisms (both mechanical and molecular) mediating osteoarthritic progression or testing various therapeutic interventions for osteoarthritis. https://grants.nih.gov/grants/guide/notice-files/NOT-AG-24-002.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/7/27
66.	Forecast: NIAMS Clinical Trial Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required) (NIH/NIAMS) NOT-AR-24-016	Examples of studies that might be supported by this new NOFO include, but are not limited to: Clinical trials focusing on the prevention or treatment of a rheumatic, musculoskeletal or skin disease or disorder; Clinical trials to investigate safety, efficacy, or effectiveness of novel therapeutic approaches for a rheumatic, musculoskeletal or skin disease or disorder; Clinical trials testing methods to increase preventive health behaviors for a rheumatic, musculoskeletal or skin disease or disorder. https://grants.nih.gov/grants/guide/notice-files/NOT-AR-24-016.html	TBD	Estimated post date: 5/31/24 Estimated proposal date: 7/2/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MUSCULOSKELETAL HEALTH		
67.	Forecast: Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional) (NIH) NOT-AR-25-004	These Centers promote collaborative basic, translational, and clinical research and provide important resources that can be used by the national muscular dystrophy research communities. The Centers also provide outstanding environments for the training of new researchers capable of addressing high priority objectives in muscular dystrophy research. https://grants.nih.gov/grants/guide/notice-files/NOT-AR-25-004.html	Up to \$1 million per year, for up to 5 years	Estimated post date: 5/1/24 Estimated proposal date: 7/3/24
68.	Forecast: FY24 Peer Reviewed Orthopaedic Research Program (DoD/CDMRP)	Four awards are anticipated: Women's Health Research, Applied Research, Clinical Trial, and Clinical Translational Research. Applications must address one or more of the Focus Areas . https://cdmrp.health.mil/pubs/press/2024/24prorppreann	Up to \$3.25 million, for up to 4 years Dependent upon award mechanism	TBD
		PALLIATIVE CARE (1)		
69.	Consortium for Palliative Care Research Across the Lifespan (U54 Clinical Trial Optional) (NIH) RFA-AG-25-002	The aim of the Consortium will be to provide resources, expertise, and coordination to advance innovative, high-quality research on palliative care for those living with serious illnesses across the lifespan. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-002.html	Up to \$9.5 million for FY25, up to \$14 million per year for FY26-FY29	Letter of intent: 5/31/24 Proposal: 7/2/24
		PATIENT-CENTERED RESEARCH (5)		
70.	Forecast: Implementing and Evaluating Patient-Centered Clinical Decision Support Strategies in Real-World Settings (U18) (AHRQ) NOT-HS-24-009	This NOFO will solicit applications to support research on patient-centered clinical decision support (PC CDS). Applicants will propose innovative collaborative research to understand how CDS tools in real-world healthcare settings can be improved to become more patient centered. https://grants.nih.gov/grants/guide/notice-files/NOT-HS-24-009.html	TBD	Estimated post date: Late Spring 2024 Estimated proposal date: Summer 2024
71.	Forecast: Advancing the Science of Engagement PCORI Funding Announcement -- Cycle 2 2024 (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes; Techniques that lead to effective engagement; How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity; How engagement supports successful research. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-2-2024	Up to \$1.5 million, for up to 3 years	System opens: 5/7/24 Letter of intent: 6/4/24 Proposal: 9/4/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
72.	Forecast: Broad Pragmatic Studies Funding Announcement - 2024 Standing PFA (Cycle 2 2024) (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research projects. All applications must align the proposed research with at least one of the National Priorities for Health. Applicants have the option to choose up to three of twelve topic themes , based on how their proposed research aligns with the themes. Cycle 2 SAEs include: PTSD, Improving Health and Quality of Life in Down Syndrome, Peripheral Arterial Disease, and Functional Sensory Impairment in Older Adults. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-funding-announcement-2024-standing-pfa-cycle-2-2024	Up to \$12 million, for up to 5 years Dependent upon award mechanism	System opens: 5/7/24 Letter of intent: 6/4/24 Proposal: 9/4/24
73.	Forecast: Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research – 2024 Standing PFA (Cycle 2 2024) (PCORI)	For this PFA, PCORI has identified the following areas as programmatic priorities: Methods to Improve the Use of AI and ML in Clinical Research; Methods to Improve Study Design; Methods to Support Data Research Networks; Methods Related to Ethical and Human Subjects Protections Issues in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-2024-standing-pfa-cycle-2-2024	Up to \$750,000, for up to 3 years	System opens: 5/7/24 Letter of intent: 6/4/24 Proposal: 9/4/24
74.	Forecast: Phased Large Awards for Comparative Effectiveness Research (PLACER) – Cycle 2 2024 (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. Applications must address at least one of the National Priorities for Health . https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-2-2024	Up to \$22 million, for up to 6.5 years	System opens: 5/7/24 Letter of intent: 6/4/24 Proposal: 9/4/24
		RARE DISEASES (1)		
75.	Forecast: Addressing Rare Diseases Topical PCORI Funding Announcement – Cycle 2 2024 (PCORI)	This Topical PFA will solicit applications proposed to address patient-centered CER questions that will fill important rare disease research gaps. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis (SAEs): Approaches to symptom management for individuals with rare disease; Approaches for timely diagnosis of rare diseases; Approaches to improving care delivery for individuals with rare diseases. Applications addressing cross-cutting issues that include more than one rare disease diagnosis are encouraged, but studies focusing on a single rare disease are also acceptable. https://www.pcori.org/funding-opportunities/announcement/addressing-rare-diseases-topical-pcori-funding-announcement-cycle-2-2024	Up to \$12 million, for up to 5 years	System opens: 5/7/24 Letter of intent: 6/4/24 Proposal: 9/4/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER (13)		
76.	NOSI: Myelin plasticity in sculpting addiction neurocircuitry (NIH/NIDA) NOT-DA-25-028	The purpose of this NOSI is to encourage innovative research on the roles of oligodendrocytes and myelination in addiction-related neurocircuit functions. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-25-028.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/7/27
77.	Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (Ro1 - Clinical Trials Optional) (NIH/NIDA) RFA-DA-25-043	This NOFO will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based, exploratory projects may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational levels. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-043.html	Up to \$350,000 per year, for up to 5 years	Letter of intent: 6/17/24 Proposal: 7/17/24
78.	Forecast: Addressing Substance Use Topical PCORI Funding Announcement -- Cycle 2 2024 (PCORI)	PCORI is particularly interested in applications focusing on substance use/misuse and substance use disorders in high-need and/or underserved populations. Applications may propose CER studies of prevention, screening, harm reduction, treatment and recovery approaches for substance use/misuse and substance use disorders at the individual, community or systems level to improve patient-centered substance-use-related outcomes. https://www.pcori.org/funding-opportunities/announcement/addressing-substance-use-topical-pcori-funding-announcement-cycle-2-2024	Up to \$12 million, for up to 5 years	System opens: 5/7/24 Letter of intent: 6/4/24 Proposal: 9/4/24
		THERAPEUTICS (5)		
79.	Interventional Agents Safety and Pharmacokinetic Services (NIH/NIAID) 75N93024R00003	The development and introduction of new therapeutic products against potential agents of bioterrorism, drug-resistant pathogens, emerging and re-emerging infectious diseases, as well as infectious diseases prevalent in resource-limited countries remains a high public health priority. To assist in filling these public health gaps, the NIAID requires a nontraditional, proactive, and product development-oriented program to provide preclinical and non-clinical development support for promising therapeutic candidates that emerge from academia, the private sector, or other sources. https://sam.gov/opp/3bd068c077a14adda236f4e0ecf91dff/view	Dependent upon contract	Proposal: 5/24/24
80.	Drug Development Tools Research Grants (U01) Clinical Trials Optional (FDA/CBER) RFA-FD-24-030	The purpose of this NOFO is to support research to continue the development of drug development tools that have an accepted or a reviewable Letter of Intent (LOI) within a drug development tool qualification program within either CBER or CDER. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-030.html	Up to \$250,000 per year, for up to 2 years	Proposal: 5/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		THERAPEUTICS		
81.	Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional (FDA/CBER/CDER) RFA-FD-24-037	The goal of this NOFO is to explore the role of DHTs in the evaluation of new drugs. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-037.html	Up to \$1.96 million, for up to 2 years	Proposal: 5/20/24
82.	Production of Drug Substances and Drug Products at Commercial Scale (BARDA/BioMaP) RPP-24-02-KSM-API	Platform Technologies for Efficient Distributed Scalable Manufacturing of Active Pharmaceutical Ingredients (APIs) Drugs, includes key regulatory/chemical starting material(s) (KSMs), precursor(s), intermediate, enzymes or catalyst necessary up to and including the synthesis of essential APIs, with a preferred application to multiple medicines. Examples of platforms include but are not limited to those that incorporate distributed manufacturing systems with a special focus on vertical integration of the systems with fill and finish lines. https://www.biomap-consortium.org/rpp-24-02-ksm-api/	Dependent upon proposal and available funding	Enhanced white papers: 3/20/24
83.	Sterilization Capacity for Vaccines and Therapeutics (BARDA/BioMaP) RPP-24-03-Sterilization	This RPP supports a strategic goal of ASPR, BARDA, and the Defense Production Act (DPA) Title III program, who are seeking to expand domestic sterilization capacity to enable U.S. suppliers to support the production of 600 million vaccine doses within six to nine months with minimal disruption to the baseline public health supply chain. This requirement is becoming increasingly acute due to the reliance on unstable global sources of supply for Cobalt 60, and an increasing reliance on alternative and emerging technologies such as X-ray or dual Electron Beam (E-Beam)/X-ray sterilization capabilities. https://www.biomap-consortium.org/rpp-24-03-sterilization/	Dependent upon proposal and available funding	Enhanced white papers: 3/28/24
		VETERINARY MEDICINE (1)		
84.	Cooperative Agreement for Long Term Data Collection on Antimicrobial Use in Animals (U01) Clinical Trial Not Allowed (FDA/CVM) RFA-FD-24-031	This NOFO will support one or more projects to 1) collect antimicrobial use data from diverse animal sectors, including domestic livestock, poultry, companion animals (dogs, cats, and horses), and minor species (e.g., fish, sheep, goats) and 2) contribute to the development of data collection frameworks, including providing data and expertise as resources and a public-private partnership frameworks are established. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-031.html	Up to \$200,000 per year, for up to 5 years	Letter of intent: 4/11/24 Proposal: 5/13/24



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		WOMEN'S HEALTH (1)		
85.	Team Science Leadership Scholars Program (LSP) in Women's Health, Autoimmune and Immune-Mediated Diseases 2.0 (NIH/FNIH) RFA-AMPAIM-LSP-23-002	The goal of the LSP is to prepare next generation leaders of team science that will improve women's health. Furthermore, an expected outcome is increased representation of women scientists among leaders of complex, high-impact research programs in academia, industry, and the public health sector. https://ampaim.omrf.org/leadership-scholar-program/	Up to \$250,000 per year, for up to 2 years	Application: 4/1/24





Recurring Opportunities

March 13, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (1)				
86.	Open-Office Broad Agency Announcement (BAA) 75N99223S0001	Awardees will develop groundbreaking new ways to tackle health-related challenges through high-potential, high-impact biomedical and health research. ARPA-H is transitioning to Mission Office-specific Innovation Solutions Openings (ISOs) and will be closing this Open-Office BAA on March 14, 2024. Submissions to the Open BAA received before this date will still be reviewed according to the current process. Individuals are encouraged to submit to the Mission Office-Specific ISO to be posted 3/15/24. View the draft presolicitation. The Mission Office ISOs areas of interest are: Health Science Futures; Proactive Health; Resilient Systems; Scalable Solutions. https://sam.gov/opp/3fb0269c6d16457cae33bb9bdcecea04/view	Dependent upon proposal and award mechanism	Abstract: 3/14/24
AIR FORCE (3)				
87.	Airman Readiness Medical Research (ARMR) Hybrid BAA FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/search-results-detail/327332	Up to \$49 million, per award	White papers accepted on rolling basis until 5/1/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE		
88.	Research Interests of the Air Force Office of Scientific Research FA9550-23-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. These areas are organized and managed in two scientific Departments: Engineering and Information Science (RTA), Physical and Biological Sciences (RTB), and our international offices (EAORD, SOARD, and AOARD). https://www.grants.gov/search-results-detail/345653	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
89.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		ARMY (8)		
90.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/f2d01f5a6c444e32af543e9519a0805f/view	Dependent upon proposal	Proposals accepted on a rolling basis through 6/11/27
91.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
92.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational Medicine; Medical Biological Defense; and Medical Chemical Defense. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
93.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; prolonged field care (PFC); human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
94.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
95.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
96.	Army Applications Lab BAA for Disruptive Applications W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/search-results-detail/315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
97.	Army Combat Capabilities Development Command Broad Agency Announcement W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/search-results-detail/327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
98.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/opp/3d6c915e3ebc489bbcd07105fb6f4ac5/view	Dependent upon proposal	Proposal: 9/25/28
99.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #15: ReDIRECT; AOI #16: Lab at Home; AOI #19: Healing Lungs; AOI #20: DRIVE Forward; AOI #22: ReBooT; AOI #24: RePAIR; AOI #25: FASTx; AOI #26: Agnostic Diagnostic; AOI #27: Stopping Secondary Spread. https://sam.gov/opp/acb2fc60fc434f239241bfc63e2e97a6/view	Up to \$750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (2)		
100.	Biological Technologies BAA HR001123S0045	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: Human Performance; Materials, Sensors, Processing; Ecosystem and Environmental; Biosecurity and Biosafety; and Biomedical and Biodefense. https://sam.gov/opp/597bf60984314db1b3ecfce393677c75/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 6/20/24
101.	Defense Sciences Office, Office-wide HR001123S0053	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Novel Materials & Structures; Sensing and Measurement; Computation and Processing; Enabling Operations; Collective Intelligence; and Emerging Threats. https://sam.gov/opp/972be70efd7e4608b01311466edf6b0f/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 9/26/24
		DEFENSE THREAT REDUCTION AGENCY (2)		
102.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-14-24-FRCWMD-BAA	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/3b8216acdcc44c46ada2511459918de5/view	Up to \$1 million per year, for up to 5 years	White papers accepted through 9/2024



	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY		
103.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): <ul style="list-style-type: none"> • Understand current and emerging WMD situations, threats, and capabilities • Enable effective and integrated WMD deterrence • Control, disable, and defeat current and emerging WMD threats • Protect the force and mitigate crises from WMD • Enable cross-cutting capabilities https://sam.gov/opp/45f3e82bc46c4d3f89560b700d1123cd/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
		DEPARTMENT OF ENERGY (1)		
104.	FY 2024 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003177	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/search-results-detail/350408	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/24
		NAVY (3)		
105.	FY23 Broad Agency Announcement for Innovative Environmental Technologies and Methodologies N3943023S2501	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/14178e9157ad40b387ddb443071b0969/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 4/11/24
106.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001424SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.nre.navy.mil/work-with-us/funding-opportunities/fy24-long-range-broad-agency-announcement-baa-navy-and-marine	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/24
107.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/opp/1e5fbd8c66d949fdb4cfe0afc8bob76b/view	Dependent upon proposal and award mechanism	White papers accepted through 12/31/24





Terms

AD/ADRD: Alzheimer's Disease / Alzheimer's Disease Related Dementias

Aoi: Area of Interest

BAA: Broad Agency Announcement

BBB: Blood-Brain Barrier

CNS: Central Nervous System

FOA: Funding Opportunity Announcement

IC: NIH Institutes and Centers

NOFO: Notice of Funding Opportunity

NOSI: Notice of Special Interest

PI: Principal Investigator

PTSD: Post-Traumatic Stress Disorder

RFI: Request for Information

RFP: Request for Proposal

SBIR: Small Business Innovation Research

SDOH: Social Determinants of Health

STTR: Small Business Technology Transfer

SUD: Substance Use Disorder

TRL: Technology Readiness Level

VCID: Vascular Contributions to Cognitive Impairment and Dementia

Agencies

ARPA-H: Advanced Research Projects Agency for Health

ASPR: Administration for Strategic Preparedness and Response

BARDA: Biomedical Advanced Research and Development Authority

CDC: Centers for Disease Control and Prevention

CDMRP: Congressionally Directed Medical Research Programs

DARPA: Defense Advanced Research Projects Agency

DHA: Defense Health Agency

DoD: Department of Defense

FDA: U.S. Food and Drug Administration

MTEC: Medical Technology Enterprise Consortium

NIH: National Institutes of Health

[Back to Table of Contents](#)

GBG Acronyms

Updated Monthly

March 13, 2024

<https://www.g2gconsulting.com/gbg-reporting-service/>

NSF: National Science Foundation

PCORI: Patient-Centered Outcomes Research Institute

USAMRDC: U.S. Army Medical Research and Development Command

USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases

USSOCOM: United States Special Operations Command

NIH Institutes and Centers

CC: NIH Clinical Center

CIT: NIH Center for Information Technology

CSR: NIH Center for Scientific Review

FIC: Fogarty International Center

NCATS: National Center for Advancing Translational Sciences

NCCIH: National Center for Complementary and Integrative Health

NCI: National Cancer Institute

NEI: National Eye Institute

NHGRI: National Human Genome Research Institute

NHLBI: National Heart, Lung, and Blood Institute

NIA: National Institute on Aging

NIAAA: National Institute on Alcohol Abuse and Alcoholism

NIAID: National Institute of Allergy and Infectious Diseases

NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases

NIBIB: National Institute of Biomedical Imaging and Bioengineering

NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development

NIDA: National Institute on Drug Abuse

NIDCD: National Institute on Deafness and Other Communication Disorders

NIDCR: National Institute of Dental and Craniofacial Research

NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases

NIEHS: National Institute of Environmental Health Sciences

NIGMS: National Institute of General Medical Sciences

NIMH: National Institute of Mental Health

NIMHD: National Institute on Minority Health and Health Disparities

NINDS: National Institute of Neurological Disorders and Stroke

NINR: National Institute of Nursing Research

NLM: National Library of Medicine

